<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for ALNY</title>
    <link />
    <description>Headlines for Alnylam Pharmaceuticals, Inc.</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Signi</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/analyst-ratings/analyst-color/13/05/3618987/update-deutsche-bank-initiates-coverage-on-alnylam-pharm.aspx</link>
      <author>Benzinga</author>
      <pubDate>Fri, 24 May 2013 08:33:38 GMT</pubDate>
    </item>
    <item>
      <title>Benzinga's Top Initiations</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/analyst-ratings/initiation/13/05/3618912/benzingas-top-initiations.aspx</link>
      <author>Benzinga</author>
      <pubDate>Fri, 24 May 2013 07:54:58 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam Pharmaceuticals' Management Presents at 2013 UBS Global Healthcare Conference (Transcript)</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1453701-alnylam-pharmaceuticals-management-presents-at-2013-ubs-global-healthcare-conference-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 22 May 2013 12:39:03 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/21/alnylam-to-webcast-presentation-at-deutsche-bank-3/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Tue, 21 May 2013 16:21:02 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting A</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/17/alnylam-presents-key-pre-clinical-proof-of-concept/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Fri, 17 May 2013 08:20:23 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam Pharmaceuticals' CEO Presents at 2013 Bank of America Merrill Lynch Health Care Conference (</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1440991-alnylam-pharmaceuticals-ceo-presents-at-2013-bank-of-america-merrill-lynch-health-care-conference-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 16 May 2013 14:23:04 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/15/alnylam-to-webcast-presentation-at-2013-ubs-global/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 15 May 2013 16:20:47 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/08/alnylam-to-webcast-presentation-at-2013-bank-of-am/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 08 May 2013 16:20:24 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam Narrows Loss, Sales Fall - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/98797/alnylam-narrows-loss-sales-fall.aspx</link>
      <author>Zacks</author>
      <pubDate>Tue, 07 May 2013 08:25:01 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1407541-alnylam-pharmaceuticals-ceo-discusses-q1-2013-results-earnings-call-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Mon, 06 May 2013 21:25:04 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/06/alnylam-pharmaceuticals-reports-first-quarter-2013/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Mon, 06 May 2013 16:21:17 GMT</pubDate>
    </item>
    <item>
      <title>Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/04/29/alnylam-to-webcast-conference-call-discussing-firs/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Mon, 29 Apr 2013 16:20:26 GMT</pubDate>
    </item>
    <item>
      <title>Pipeline Progresses at ViroPharma - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/97732/pipeline-progresses-at-viropharma.aspx</link>
      <author>Zacks</author>
      <pubDate>Tue, 23 Apr 2013 17:50:01 GMT</pubDate>
    </item>
    <item>
      <title>The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1361691-the-beginning-of-a-shift-at-tekmira-from-focus-on-delivery-to-therapy.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 23 Apr 2013 11:53:00 GMT</pubDate>
    </item>
    <item>
      <title>FDA Approves Novartis' Simbrinza - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/97613/fda-approves-novartis-simbrinza.aspx</link>
      <author>Zacks</author>
      <pubDate>Mon, 22 Apr 2013 17:20:01 GMT</pubDate>
    </item>
    <item>
      <title>Best Stocks: Biotech Still Holding Top Spots</title>
      <link>http://www.fool.com/news/xt/nasdaq/www.nasdaq.com/article/best-stocks-biotech-still-holding-top-spots-cm239083.aspx</link>
      <author>Nasdaq</author>
      <pubDate>Mon, 22 Apr 2013 10:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Best Stocks: Biotech Still Holding Top Spots</title>
      <link>http://www.fool.com/news/xt/minyanville/www.minyanville.com/sectors/biotech-pharma/articles/best-stocks253a-biotech-remains-at-the/4/22/2013/id/49384.aspx</link>
      <author>Minyanville</author>
      <pubDate>Mon, 22 Apr 2013 10:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Best Stocks: Four New Names, Four New Buys</title>
      <link>http://www.fool.com/news/xt/minyanville/www.minyanville.com/trading-and-investing/stocks/articles/best-stocks253a-four-new-names-four/4/15/2013/id/49253.aspx</link>
      <author>Minyanville</author>
      <pubDate>Mon, 15 Apr 2013 09:30:00 GMT</pubDate>
    </item>
    <item>
      <title>Biotechs With Staggering Potential: Grant Zeng</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1323201-biotechs-with-staggering-potential-grant-zeng.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 05 Apr 2013 10:19:13 GMT</pubDate>
    </item>
    <item>
      <title>Cramer's Mad Money - Which Company Should Buy Netflix? (4/3/13)</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1319711-cramer-s-mad-money-which-company-should-buy-netflix-4-3-13.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 04 Apr 2013 07:00:42 GMT</pubDate>
    </item>
  </channel>
</rss>
